Active	Status	Sponsor type	Region	Phase	Filter
24 Active 66 Inactive 90 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lee, Jong Mog
NCT04497142: Effect of Perampanel on Peritumoral Hyperexcitability in HGG	Completed	1/2	12	US	Perampanel, E2007, Fycompa, Standard of Care, Standard treatment (typically the anti-seizure medication levetiracetam)	Dana-Farber Cancer Institute, National Cancer Institute (NCI), Eisai Inc.	Glioma, Malignant, Surgery, Seizures	05/23	05/23
NCT04409080 / 2020-002031-29: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy	Suspended	1/2	33	Europe, US, RoW	REGN7257	Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc	Severe Aplastic Anemia (SAA)	01/26	07/26
Ahn, Joong B
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy	Recruiting	2	464	Europe, RoW	Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo	Chiesi Farmaceutici S.p.A.	Uncontrolled Asthma	12/25	12/25
Hwang, Sunjin
MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)	Withdrawn	2	76	RoW	Vactosertib, Imatinib	MedPacto, Inc.	Dermoid	05/22	05/22
KEYNOTE 900, NCT03724851: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer	Active, not recruiting	1/2	120	RoW	TEW-7197, vactosertib	MedPacto, Inc., Merck Sharp & Dohme LLC	Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	05/24	01/25
NCT03698825: TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer	Completed	1/2	62	RoW	TEW-7197, vactosertib	MedPacto, Inc.	Metastatic Gastric Cancer	01/22	12/22
MP-VAC-203, NCT03732274: Phase 1b/2a, Open-label Study of Vactosertib in Combination with Durvalumab in Advanced NSCLC	Active, not recruiting	1/2	60	RoW	TEW-7197, vactosetib	MedPacto, Inc., AstraZeneca	Non-Small Cell Lung Cancer Metastatic	05/24	12/24
Lee, Jiyeon
No trials found